Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)

NCT01775462 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

X-Linked Hypohidrotic Ectodermal Dysplasia

Interventions

DRUG: EDI200

Sponsor

Edimer Pharmaceuticals